Dose to the Contralateral Breast From Radiotherapy and Risk of Second Primary Breast Cancer in the WECARE Study
Creators
- 1. Department of Radiation Physics, University of Texas M. D. Anderson Cancer Center, Houston, TX (United States)
- 2. Department of Preventive Medicine, University of Southern California, Los Angeles, CA (United States)
- 3. Department of Medicine, Vanderbilt University Medical Center, Nashville, TN (United States)
- 4. International Epidemiology Institute, Rockville, MD (United States)
- 5. Radiation Effects Research Foundation (RERF), Hiroshima (Japan)
- 6. Institute of Cancer Epidemiology, Danish Cancer Society, Copenhagen (Denmark)
- 7. Department of Radiation Oncology, University of Texas M. D. Anderson Cancer Center, Houston, TX (United States)
- 8. Department of Statistics, Memorial Sloan-Kettering Cancer Center, New York, NY (United States)
- 9. Department of Cancer Etiology, City of Hope National Medical Center, Duarte, CA (United States)
- 10. Department of Epidemiology, University of Iowa, Iowa City, IA (United States)
- 11. Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA (United States)
- 12. Department of Epidemiology, University of California, Irvine, CA (United States)
- 13. Department of Radiation Oncology, New York School of Medicine, New York, NY (United States)
- 14. Department of Radiation Oncology, Mount Sinai School of Medicine, New York, NY (United States)
Description
Purpose: To quantify the risk of second primary breast cancer in the contralateral breast (CB) after radiotherapy (RT) for first breast cancer. Methods and Materials: The study population included participants in the Women's Environmental, Cancer, and Radiation Epidemiology study: 708 cases (women with asynchronous bilateral breast cancer) and 1399 controls (women with unilateral breast cancer) counter-matched on radiation treatment. Participants were <55 years of age at first breast cancer. Absorbed doses to quadrants of the CB were estimated. Rate ratios (RR) and 95% confidence intervals (CI) were calculated using multivariable-adjusted conditional logistic regression models. Results: Across all patients, the mean radiation dose to the specific quadrant of the CB tumor was 1.1 Gy. Women <40 years of age who received >1.0 Gy of absorbed dose to the specific quadrant of the CB had a 2.5-fold greater risk for CB cancer than unexposed women (RR = 2.5, 95% CI 1.4-4.5). No excess risk was observed in women >40 years of age. Women <40 years of age with follow-up periods >5 years had a RR of 3.0 (95% CI 1.1-8.1), and the dose response was significant (excess RR per Gy of 1.0, 95% CI 0.1-3.0). Conclusions: Women <40 years of age who received a radiation dose >1.0 Gy to the CB had an elevated, long-term risk of developing a second primary CB cancer. The risk is inversely related to age at exposure and is dose dependent
Availability note (English)
Available from http://dx.doi.org/10.1016/j.ijrobp.2008.02.040Additional details
Identifiers
- DOI
- 10.1016/j.ijrobp.2008.02.040;
- PII
- S0360-3016(08)00348-9;
Publishing Information
- Journal Title
- International Journal of Radiation Oncology, Biology and Physics
- Journal Volume
- 72
- Journal Issue
- 4
- Journal Page Range
- p. 1021-1030
- ISSN
- 0360-3016
- CODEN
- IOBPD3
INIS
- Country of Publication
- United States
- Country of Input or Organization
- International Atomic Energy Agency (IAEA)
- INIS RN
- 40047631
- Subject category
- S62: RADIOLOGY AND NUCLEAR MEDICINE;
- Descriptors DEI
- CARCINOMAS; EPIDEMIOLOGY; MAMMARY GLANDS; PATIENTS; RADIATION DOSES; RADIATION HAZARDS; RADIOTHERAPY; WOMEN
- Descriptors DEC
- ANIMALS; BODY; DISEASES; DOSES; FEMALES; GLANDS; HAZARDS; HEALTH HAZARDS; MAMMALS; MAN; MEDICINE; NEOPLASMS; NUCLEAR MEDICINE; ORGANS; PRIMATES; RADIOLOGY; THERAPY; VERTEBRATES
Optional Information
- Copyright
- Copyright (c) 2008 Elsevier Science B.V., Amsterdam, The Netherlands, All rights reserved.